Company: CDT
Filing Date: 2025-07-31
Form Type: S-3
Source: 0001641172-25-021729
Chunk: 8

Company: CDT Equity Inc.
Filing Date: 2025-07-31
Form: S-3
Chunk 8
---
 in the pharmaceutical industry. By reducing reliance on traditional, labor-intensive methods and harnessing the power of AI-driven technology, Conduit is well-positioned to lead in areas such as drug repurposing, clinical trial monitoring, and IP creation, ensuring the Company’s long-term growth and market leadership.

Furthermore, Conduit believes that it is well positioned to pursue, and intends to pursue, additional relationships and/or partnerships with third parties for the licensing of further assets which are currently deprioritized. We plan to focus our efforts on developing clinical assets to address disorders that impact a large population where there is no present treatment or the present treatment, carries significant unwanted side effects.

| 3 |

Recent Developments Regarding the Selling Stockholders

Joint Development Agreement

On June 3, 2025, the Company entered into the Joint Development Agreement with Manoira which granted Manoira a non-exclusive, non-transferable, non-sublicensable, fully paid-up, royalty-free license to the intellectual property rights related to the pharmaceutical compounds known individually and together as AZD1656 and AZD5658 (the “Conduit Assets”). Manoira will evaluate the Conduit Assets’ applicability in animal health, explore veterinary market opportunities, and provide data from the evaluations to inform Conduit’s human clinical programs. The license does not grant Manoira the right to distribute, market, promote or sell the products or services that are related to or incorporate the Conduit Assets.

In connection with $500,000 to be paid by the Company to Manoira, the Company issued 154,799 shares. The Company has no future costs owed to Manoira, nor any future consideration due to the Company as a result of the Joint Development Agreement, with the exception that the Company may benefit from the grant to Manoira of intellectual property rights of which Manoira will evaluate the applicability in animal health, explore veterinary market opportunities, and provide data from the evaluations to inform the Company’s human clinical programs.

Manoira is considered to be a related party of the Company, as Dr. Andrew Regan, Chief Executive Officer of Conduit and member of Conduit’s board of directors, is also the sole director of Manoira. In addition, Manoira is an entity controlled by Dr. Andrew Regan.

Harold Eytan Consulting Agreement

On June 27, 2025, Harold Eytan and the Company entered into the Consulting Agreement in which Harold Eytan will provide services to optimize strategies